Stocktoria
Lantheus Holdings, Inc. LNTH
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 2015-06-25
Lantheus Holdings, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 61.1% | 64.4% | 54.7% | 62.2% | 44.1% |
| Operating margin | 20.2% | 29.8% | 28.1% | 3.9% | -14.3% |
| Net margin | 15.2% | 20.4% | 25.2% | 3.0% | -16.8% |
| Return on assets | 10.5% | 15.8% | 19.8% | 2.1% | -8.3% |
| Return on equity | 21.4% | 28.7% | 40.0% | 6.3% | -15.3% |
| Debt / equity | — | — | — | 1.25× | 0.38× |
| Current ratio | 2.70 | 5.52 | 5.80 | 2.74 | 2.61 |
| Revenue growth | 0.5% | 18.3% | 38.6% | 119.9% | 25.3% |
Source: SEC EDGAR filings · CIK 0001521036 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.